Primary open-angle glaucoma, or POAG, is the most common form of glaucoma worldwide and a leading cause of permanent vision loss. Because it progresses slowly and often without symptoms in its early stages, many patients live with the disease for decades, managing daily eye drops, attending regular monitoring appointments, and coping with the knowledge that any vision they lose will never come back. This chronic, unpredictable nature makes glaucoma not just an ophthalmological problem but a psychological one, and it is precisely this intersection that the new study set out to explore.

The research team, led by Yihong Zhu, Wanting Shu, Jiamin Xie and Xueli Chen of Shanghai General Hospital and Shanghai Jiao Tong University School of Medicine, together with biostatistician Wei Zhang of Fudan University, recruited 124 outpatients diagnosed with primary open-angle glaucoma. Between August 2024 and January 2025, each participant completed a battery of standardized questionnaires designed to capture three distinct dimensions of their experience: how their vision affects daily life, how much social support they perceive, and how much psychological distress they carry.

To measure vision-related quality of life, the researchers used the 25-Item National Eye Institute Visual Function Questionnaire, widely regarded as the gold standard for assessing how eye disease affects activities such as reading, driving, and navigating one’s surroundings. Social support was assessed with the Social Support Rating Scale, which gauges the degree of emotional, practical, and informational backing a patient receives from family, friends, and community. Psychological distress was captured with the four-item Patient Health Questionnaire, a compact screening tool that combines symptoms of depression and anxiety into a single score. Socio-demographic details, including education, income, smoking history, and the presence of other chronic illnesses, were collected at the same time.

The initial, univariate analyses painted a familiar but sobering picture. Patients with lower educational attainment reported poorer vision-related quality of life, as did those who felt a heavier economic burden from their glaucoma treatment, those living with chronic comorbid conditions, and those who formerly or currently smoked. Each of these factors was statistically associated with worse self-reported functioning and well-being, with the strongest signals coming from education and financial strain, both at P values below 0.001.

But the more revealing findings emerged when the researchers moved to multiple regression analysis, a statistical technique that allows scientists to determine which factors retain their explanatory power once the overlapping effects of the others are accounted for. When the psychological distress score was added to the model, the picture shifted dramatically. Psychological distress, economic burden, and smoking remained significant predictors of quality of life. The associations for social support and education, however, were attenuated — weakened to the point of losing statistical significance. In other words, much of what had appeared to be a direct benefit of social support seemed to operate through a psychological channel.

To test this possibility formally, the team conducted a mediation analysis, a method that decomposes the relationship between two variables into a direct effect and an indirect effect that passes through a third variable. The results were striking. The indirect effect of social support on vision-related quality of life, transmitted through psychological distress, was statistically significant, with a path coefficient of 0.185 and a P value below 0.001. The direct effect — the portion of the relationship not explained by distress — was not statistically significant, with a coefficient of 0.312 and a P value of 0.081. Taken together, these numbers suggest that psychological distress may account for a substantial portion of the observed association between social support and how glaucoma patients experience their vision in daily life.

The interpretation, the authors caution, is correlational rather than causal. Because the study is cross-sectional — a snapshot of a single moment in time — it cannot establish whether low social support causes psychological distress, whether distress causes patients to perceive less support, or whether both are shaped by some other factor such as disease severity. The researchers are explicit on this point, noting that longitudinal studies are needed to confirm the directionality of the relationships they observed. Still, the pattern they uncovered is consistent with a plausible biological and psychological mechanism: social connections may buffer the emotional toll of living with a progressive, sight-threatening disease, and it is this buffering — rather than any direct practical assistance — that preserves quality of life.

The clinical implications could be significant. If psychological distress is indeed the pathway through which social support exerts its influence, then screening for anxiety and depression could become as routine in glaucoma clinics as measuring intraocular pressure. The authors suggest that integrating psychological distress screening into standard glaucoma care may hold real value, allowing ophthalmologists to identify patients who are struggling emotionally and to connect them with mental health resources before distress compounds the burden of vision loss. Such an approach would represent a shift toward truly holistic care for a disease that has traditionally been managed almost exclusively through pressure-lowering drops, laser treatment, and surgery.

The study also carries a broader message about how medicine measures success. For a patient with glaucoma, a stable visual field on paper does not necessarily mean a good life. The findings underscore that quality of life in chronic eye disease is woven from social, economic, and psychological threads as much as from clinical ones, and that interventions aimed at strengthening social support may pay dividends precisely because they ease the anxiety and depression that so often accompany progressive vision loss. As the global population ages and the number of people living with glaucoma continues to climb, research like this reminds clinicians and researchers alike that the goal of treatment is not merely to preserve sight, but to preserve the person behind the eyes.

Subject of Research: Psychological distress as a mediator between social support and vision-related quality of life in primary open-angle glaucoma

Article Title: Beyond vision loss: psychological distress as a potential pathway linking social support to vision-related quality of life in glaucoma

Article References: Zhu, Y., Shu, W., Xie, J., Zhang, W., & Chen, X. (2026). Beyond vision loss: psychological distress as a potential pathway linking social support to vision-related quality of life in glaucoma. BMC Psychology. https://doi.org/10.1186/s40359-026-05737-2

Image Credits: AI Generated

DOI: 10.1186/s40359-026-05737-2

Keywords: glaucoma, primary open-angle glaucoma, psychological distress, social support, quality of life, vision-related quality of life, mediation analysis, anxiety, depression, NEI-VFQ-25, mental health screening, ophthalmology

The research, published in BMC Health Services Research, was conducted by a team led by Ravi Dhar Bhandari of Dhangadhi Netralaya Eye Hospital together with colleagues from the Tilganga Institute of Ophthalmology in Kathmandu. Their focus was a specific behavior known in the health services literature as cost-related non-adherence, abbreviated CRNA. The concept is deceptively simple: a patient is considered cost-related non-adherent if, within a defined period, they engaged in at least one cost-saving behavior related to their medication. That might mean skipping doses to make a bottle last longer, taking drops less frequently than prescribed, delaying a refill until money becomes available, or using a cheaper substitute without medical guidance. Each of these behaviors may seem minor in isolation, but in a disease where sustained intraocular pressure control is the only proven way to preserve vision, even intermittent lapses can translate into permanent nerve damage.

To measure how often this happens, the researchers designed a cross-sectional study running from 1 October 2023 to 31 March 2024 at Dhangadhi Netralaya, a major eye hospital serving Sudurpaschim Province. They enrolled consecutive patients aged eighteen or older who had been receiving topical glaucoma medication for at least six months, a threshold chosen to ensure that participants had enough experience with their treatment regimen to report on it meaningfully. Data came from two sources: a structured questionnaire capturing sociodemographic information and medication-related behaviors, and a review of medical records for clinical details such as diagnosis, visual acuity, and the number of medication bottles prescribed. The study received ethics approval from the Ethical Review Committee of the Nepal Health Research Council under protocol reference number 54, and every participant provided written informed consent before enrollment, in accordance with the Declaration of Helsinki.

The final cohort comprised 132 patients, of whom 60.6 percent were male, with a mean age of 60.1 years and a standard deviation of 12.6 years. Primary open-angle glaucoma, the most common form of the disease worldwide, accounted for 65.9 percent of diagnoses, with angle-closure variants and secondary glaucomas making up the remainder. The burden of visual loss in this group was striking even before adherence was considered: 53.0 percent of participants already had some degree of visual impairment, and 15.2 percent were blind. These figures underscore a broader reality of glaucoma care in low-resource settings, where patients frequently present late in the disease course, when much of the damage cannot be undone. Against this backdrop, any additional barrier to effective treatment, including cost, becomes a matter of profound consequence.

The headline finding was that 14 of the 132 participants reported at least one cost-saving behavior with their glaucoma medications in the preceding six months, yielding a prevalence of cost-related non-adherence of 10.6 percent, with a 95 percent confidence interval ranging from 6.1 to 17.5 percent. In other words, roughly one in ten patients in this cohort was compromising their glaucoma therapy for financial reasons. The authors are careful to frame this as a conservative estimate for a single hospital population, but the proportion is clinically meaningful: every one of those ten percent represents a person whose optic nerve is exposed to pressure fluctuations that could accelerate vision loss. The confidence interval also indicates genuine statistical uncertainty inherent in a sample of this size, a limitation the researchers acknowledge by presenting the estimate transparently rather than overstating its precision.

Perhaps the most technically interesting part of the study lies in its analysis of which patients were most at risk. The team first performed bivariate analyses examining the raw associations between cost-related non-adherence and a range of potential predictors, then moved to multivariable logistic regression to adjust for confounding variables and isolate independent risk factors. Three factors emerged with statistical significance at the conventional threshold of a p-value below 0.05. Patients with systemic comorbidities, meaning coexisting conditions such as diabetes, hypertension, or other chronic illnesses requiring their own treatment expenses, had dramatically higher odds of cost-related non-adherence, with an adjusted odds ratio of 23.05 and a 95 percent confidence interval spanning 2.32 to 374.36. The very width of that interval reflects the small number of affected patients, but the direction and magnitude of the association tell a coherent story: households juggling multiple chronic diseases face compounding out-of-pocket costs, and when budgets are stretched, eye drops that produce no felt benefit are among the first expenses to be cut.

The second independent predictor was the number of glaucoma medication bottles prescribed. Most participants, 62.9 percent, were prescribed a single bottle, while 28.8 percent were prescribed two and 8.3 percent were prescribed three. Each additional bottle multiplied both the direct cost and the logistical complexity of the regimen, and patients on multi-bottle therapy had an adjusted odds ratio of 6.76 for cost-related non-adherence, with a confidence interval of 2.31 to 25.73. This finding aligns with a well-established principle in adherence research: regimen complexity is one of the most reliable predictors of non-adherence across virtually every chronic disease, from HIV to hypertension to glaucoma. Every additional medication adds a set of instructions, a schedule, and a price tag, and in a setting where patients typically pay out of pocket, the financial gradient is steep.

The third finding was more counterintuitive. Male sex was associated with significantly lower odds of cost-related non-adherence, with an adjusted odds ratio of 0.11 and a confidence interval of 0.02 to 0.55. Given that men made up the majority of the cohort, this suggests that women in this population face disproportionate financial barriers to sustaining their glaucoma therapy. The authors do not over-interpret this result, but it resonates with a substantial body of literature from South Asia documenting gender inequities in healthcare access and expenditure, where women’s health needs are often deprioritized within household spending decisions. Whether the mechanism in Sudurpaschim Province reflects income disparities, decision-making dynamics, or other factors is a question the study raises but cannot fully resolve, and it is precisely the kind of question that deserves targeted follow-up research.

It is worth pausing on why these findings matter beyond Nepal. Glaucoma is the leading cause of irreversible blindness globally, and the World Health Organization has projected that the burden of blinding eye disease will grow as populations age. In high-income countries, cost-related non-adherence to glaucoma drops is also documented, but insurance coverage, generic options, and pharmaceutical assistance programs provide buffers that simply do not exist in many low- and middle-income settings. In far-western Nepal, where geographic isolation, limited transportation infrastructure, and low household incomes compound the challenge, the out-of-pocket cost of a bottle of topical medication can represent a substantial fraction of a family’s monthly budget. The study’s finding that more than half of enrolled patients already had visual impairment, and one in seven was blind, paints a picture of a population arriving at care late and then struggling to sustain it.

The authors conclude with a set of practical implications that follow directly from their data. Because cost-related non-adherence affected approximately one in ten patients, and because the strongest risk factors were systemic comorbidities and multi-bottle regimens, interventions can be targeted with reasonable precision. Strategies to reduce out-of-pocket costs, whether through subsidized medication supply, inclusion of glaucoma drops in essential drug programs, or tiered pricing at charitable eye hospitals, would address the financial barrier at its root. Simplifying treatment regimens where clinically feasible, for example by favoring combination drops that consolidate multiple medications into a single bottle, would simultaneously lower cost and reduce complexity. Clinicians could also screen for cost-related non-adherence proactively, asking patients directly whether they have stretched or skipped drops for financial reasons, since patients rarely volunteer this information unprompted. As a modifiable barrier, medication cost stands apart from demographic risk factors that cannot be changed, which is what makes this modest study of 132 patients in far-western Nepal a small but genuinely actionable piece of the global effort to prevent avoidable blindness.

Subject of Research: Cost-related non-adherence to topical glaucoma medication among patients in far-western Nepal

Article Title: Cost-related non-adherence to glaucoma medical therapy: a hospital based study in Sudurpaschim Province of Nepal

Article References: Bhandari, R. D., Bist, J., Poudel, M., Pant, O. P., & Pant, B. P. (2026). Cost-related non-adherence to glaucoma medical therapy: a hospital based study in Sudurpaschim Province of Nepal. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15788-1

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15788-1

Keywords: glaucoma, cost-related non-adherence, medication adherence, Nepal, eye health, ophthalmology, health services research, out-of-pocket costs, visual impairment, primary open-angle glaucoma, treatment regimen complexity, low-resource settings

The study, conducted by ophthalmologist Arkadiy Yadgarov of Omni Eye Atlanta, examined 85 eyes with primary open-angle glaucoma, the most common form of the disease, that received the travoprost intracameral implant known commercially as iDose TR. The device is a titanium implant measuring just 1.8 by 0.5 millimeters, preloaded on a sterile single-use inserter and anchored into the sclera at the iridocorneal angle through a clear corneal incision. Once seated in the trabecular meshwork, it elutes a steady supply of travoprost, a prostaglandin analogue that enhances uveoscleral outflow of aqueous humor, the fluid whose accumulation drives dangerous pressure inside the eye.

What makes the implant conceptually powerful is that it decouples drug delivery from patient behavior. Decades of research have shown that chronic eyedrop therapy is undermined by nonadherence, with many patients missing doses or abandoning regimens entirely, and by the ocular surface disease caused by preservatives and active ingredients in the drops themselves. Fluctuating intraocular pressure between doses contributes to disease progression, and the American Academy of Ophthalmology has recently acknowledged medication reduction as a treatment endpoint comparable in importance to pressure reduction when judging surgical success. Procedural pharmaceuticals like iDose TR and its bimatoprost counterpart Durysta are designed to sidestep these failures entirely by providing consistent, sustained elution regardless of whether a patient remembers to instill a drop.

In the new study, the implant was used as a standalone procedure in 40 eyes and combined with minimally invasive glaucoma surgery, or MIGS, in 45 eyes. The combined cases most frequently paired iDose TR with the iStent infinite, a third-generation trabecular microbypass stent that enhances outflow through the conventional trabecular pathway — a complementary mechanism to the uveoscleral outflow boosted by travoprost. Sixteen eyes received the implant, the stent, and phacoemulsification cataract surgery together, while seven eyes received the implant with other MIGS procedures, with or without cataract surgery. The surgeon’s rationale was straightforward: combining modalities that act on different outflow pathways might achieve additive pressure control and a deeper reduction in medication dependence than either approach alone.

The results were striking across the board. Mean intraocular pressure fell from 17.2 millimeters of mercury at baseline to 14.5 millimeters at three months, a reduction of 2.7 millimeters of mercury, or 15.7 percent, with a p value below 0.001. Mean medication burden dropped from 1.9 medications per eye to 0.9, a 52.6 percent reduction. The proportion of eyes achieving pressures of 18 millimeters of mercury or lower rose from 63.5 percent to 81.2 percent, and the proportion reaching 12 millimeters or lower — a threshold often required in more advanced disease — nearly doubled from 17.6 percent to 40 percent. Most dramatically, the fraction of eyes completely free of eyedrops jumped from 7.1 percent before surgery to 47.1 percent at three months, meaning 40 percent of eyes that had been on medications at baseline became medication-free.

Subgroup analyses added an important layer to the findings. Pressure and medication reductions were statistically significant in every subgroup examined, whether stratified by disease severity, by surgical category, or by race and ethnicity, and there were no significant between-subgroup differences in pressure outcomes. Notably, the cohort included 29.4 percent Black patients, a group historically underrepresented in glaucoma device trials despite carrying an elevated risk of disease progression and surgical failure. The absence of any detectable difference in outcomes between White and Black patients in this series offers preliminary reassurance that the technology performs consistently across a diverse real-world population, though the authors caution that the subgroups were small and unmatched.

The one statistically significant between-group difference emerged in the surgical category comparison: combined procedures produced significantly greater medication reduction than standalone implantation. Eyes receiving iDose TR plus iStent infinite reduced their medication count by 1.2 from a baseline of 2.4, while eyes receiving the implant, stent, and phacoemulsification together achieved a reduction of 1.4 from a baseline of 1.7. Standalone implantation, by contrast, reduced medications by 0.8 from a baseline of 1.6. The investigators attribute this additive effect to the simultaneous enhancement of two distinct aqueous outflow mechanisms — uveoscleral outflow from the travoprost implant and trabecular outflow from the microbypass stent — with the continuous, stable drug elution potentially outperforming topical drops by circumventing the peak-and-trough pharmacokinetics of eyedrop dosing.

Safety results were equally encouraging. There were no intraoperative complications in any of the 85 eyes, and only two postoperative adverse events were recorded, each affecting a single eye. One eye experienced a pressure spike of at least 10 millimeters of mercury above baseline at one month, which occurred after the patient was inadvertently advised to stop all eyedrops; restarting the previous medication brought the pressure down to 10 millimeters of mercury by three months. The other event was a branch retinal vein occlusion in a patient with severe glaucoma, systemic hypertension, and a history of three prior glaucoma procedures, managed with an intravitreal anti-VEGF injection after retina consultation. No severe or sight-threatening complications occurred, no device dislodgement or explantation was needed, and no secondary glaucoma interventions were required during the follow-up period.

The comparatively modest pressure reduction in this study, relative to the 5.5 to 8.5 millimeter reductions reported in iDose TR’s pivotal clinical trials, reflects a fundamental difference in the patient population rather than a failure of the device. Clinical trials typically wash patients off medications before measuring baseline pressure, yielding starting pressures of 24 to 25 millimeters of mercury, whereas this real-world cohort began at a medicated average of 17.2 millimeters. Because higher starting pressures leave more room for improvement, the smaller absolute reduction here is expected. The cohort also included 35 percent severe glaucoma — a group excluded from the pivotal trials — and medications were titrated more cautiously in these advanced eyes, which may have tempered the medication reduction as well.

The study’s limitations are real and worth weighing: it was retrospective, nonrandomized, single-center, and followed patients for only three months, and the subgroup analyses should be treated as exploratory until validated in larger, matched cohorts. Still, the message for patients and clinicians is compelling. A procedure lasting minutes, performed through a microscopic incision, can deliver months of continuous glaucoma medication from a device the size of a grain of rice, and when layered with a trabecular stent it can free nearly half of patients from eyedrops altogether. As the field pivots toward what its proponents call interventional glaucoma — treating the disease earlier and more decisively with procedural tools rather than relying on lifelong drop adherence — this study provides some of the strongest real-world evidence yet that multimodal, multimechanism therapy can deliver on that promise safely.

Subject of Research: Real-world outcomes of the travoprost intracameral implant used alone or combined with minimally invasive glaucoma surgery

Article Title: Travoprost Intracameral Implant as a Standalone Procedure or Combined with Minimally Invasive Glaucoma Surgery (MIGS)

Article References: Yadgarov, A. (2026). Travoprost Intracameral Implant as a Standalone Procedure or Combined with Minimally Invasive Glaucoma Surgery (MIGS). Advances in Therapy. https://doi.org/10.1007/s12325-026-03778-y

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03778-y

Keywords: glaucoma, iDose TR, travoprost implant, MIGS, intraocular pressure, iStent infinite, procedural pharmaceuticals, ophthalmology, medication adherence, interventional glaucoma, phacoemulsification, primary open-angle glaucoma

The research team, led by Ziyao Liu of the Second Affiliated Hospital of Xi’an Jiaotong University, began with a simple premise. Oxidative stress, the imbalance that lets reactive oxygen species overwhelm cellular antioxidant defenses, is a well-established contributor to optic nerve degeneration. But which of the hundreds of oxidation-related genes actually matter in POAG? To find out, the investigators assembled a comprehensive set of 885 oxidative stress-related genes from the GeneCards and MSigDB databases, then mined five public transcriptomic datasets from the Gene Expression Omnibus, using optic nerve head astrocyte samples from the GSE9963 cohort as their discovery set.

The screening pipeline was deliberately redundant. Weighted gene co-expression network analysis grouped genes into modules correlated with disease status, while two independent machine learning algorithms, LASSO regression and support vector machine recursive feature elimination, each flagged candidate genes under ten-fold cross-validation. When the three approaches were intersected, only two genes survived: FXN and CYP1B1. Of these, FXN proved the sharper diagnostic blade. Receiver operating characteristic analysis in the discovery cohort yielded an area under the curve of 0.945 for FXN, far exceeding CYP1B1’s 0.700, and the result held up across four independent validation datasets with AUC values ranging from 0.708 to 0.946.

A diagnostic meta-analysis pooling the five datasets strengthened the case further. Elevated FXN expression was significantly associated with POAG status, with an overall odds ratio of 6.35. Notably, FXN levels tracked with disease sample type but not with race, gender, or age, suggesting the signal reflects disease biology rather than demographic confounders. Bioinformatic characterization placed the protein in the cytosol and mitochondria, consistent with its known role in mitochondrial iron transport and respiration, and the team retrieved its three-dimensional structure from the AlphaFold database to support future drug design efforts.

The immune dimension added another layer of intrigue. CIBERSORT deconvolution showed that POAG samples with high FXN expression differed in estimated immune cell abundance, with M1 and M2 macrophage subtypes significantly reduced in the discovery cohort. Single-sample gene set enrichment analysis linked high FXN expression to signatures including antigen-presenting cell function, chemokine receptor interaction, and inflammation promotion, although these immune associations were less consistent across the validation cohorts. Metabolic profiling told a clearer story: gene set enrichment analysis repeatedly tied high FXN expression to glycolysis and pyruvate metabolism gene sets, hinting that FXN may participate in the metabolic reprogramming that accompanies glaucomatous degeneration.

Bioinformatics alone, however, could not establish causation. The team turned to an in vitro model in which retinal ganglion cell-derived R28 cells are injured by a 12-hour exposure to 200 micromolar hydrogen peroxide, a widely used simulation of oxidative stress injury in glaucoma research. Interestingly, while FXN was upregulated in patient tissue samples, hydrogen peroxide sharply decreased FXN expression in the cultured cells. That inverse response suggested a defensive role: the stressed cells were losing a protective factor. The researchers tested this by manipulating FXN with overexpression vectors and short hairpin RNAs, verifying the changes by quantitative PCR and western blot.

The functional assays were strikingly consistent. CCK8 and EdU assays showed that hydrogen peroxide suppressed cell survival, that FXN overexpression blunted this loss of viability, and that FXN knockdown made it worse. Flow cytometry using the BODIPY-C11 probe revealed that FXN overexpression significantly reduced the reactive oxygen species surge induced by peroxide treatment, while silencing FXN accelerated ROS accumulation. Annexin V staining and TUNEL assays confirmed the anti-apoptotic effect, with FXN overexpression defending cells against both early and late apoptosis. Western blots added a mechanistic clue: FXN overexpression increased levels of the antioxidant proteins NRF2, HO-1, and SOD1, while knockdown decreased them, indicating that frataxin bolsters the cell’s endogenous antioxidant defenses.

The deeper question was who controls FXN in the first place. Mining the hTFtarget and GeneCards databases produced four candidate transcription factors: MAX, YY1, RAD21, and CTCF. Cross-referencing public knockdown data from the KnockTF database and expression correlations in the discovery dataset narrowed the field, and PCR experiments in R28 cells delivered the verdict: only silencing CTCF downregulated FXN. CTCF, a zinc-finger protein famous for organizing chromatin into loops and insulating genes from inappropriate regulatory influences, emerged as the upstream switch. Chromatin immunoprecipitation sealed the argument, showing that CTCF antibody pulled down the FXN promoter sequence spanning bases 1797 to 1815 upstream of the transcription start site, one of four predicted binding sites.

The rescue experiments tied the axis together. CTCF expression itself dropped in the hydrogen peroxide model, mirroring FXN. Overexpressing CTCF preserved cell viability, reduced ROS accumulation, and curbed apoptosis just as FXN overexpression did, but when the researchers simultaneously knocked down FXN, much of that protection evaporated. In other words, CTCF shields retinal ganglion cells largely by switching on frataxin. Because CTCF is a global regulator, the team also intersected their 125 oxidative stress-related differentially expressed genes with predicted CTCF targets and found 79 overlaps, suggesting the CTCF-FXN axis may sit within a broader oxidative stress transcriptional network in POAG.

The authors are candid about the limitations. There is no animal model yet, the acute hydrogen peroxide model cannot fully reproduce the chronic oxidative environment of human glaucoma, and the regulatory mechanism still needs confirmation through promoter mutation assays and in vivo work. The immune findings require experimental validation, and whether FXN directly modulates mitochondrial ROS production remains open. Even so, the study delivers something glaucoma research has lacked: a biomarker with validated diagnostic performance across multiple cohorts, a plausible mechanistic story connecting oxidative stress, mitochondrial biology, and chromatin regulation, and a therapeutic hypothesis that could be tested. If frataxin’s protective power holds up in living retinae, the CTCF-FXN axis may become more than a molecular curiosity. It could become a target, and for a disease that currently can only be slowed, that would be a genuinely new frontier.

Subject of Research: The role of the CTCF-FXN regulatory axis in oxidative stress, diagnosis, and progression of primary open-angle glaucoma

Article Title: CTCF-FXN regulatory axis plays critical roles in clinical assessments and disease progression of primary open-angle glaucoma

Article References: Cai, D., Yu, Y., Ma, J., Li, T., & Liu, Z. (2026). CTCF-FXN regulatory axis plays critical roles in clinical assessments and disease progression of primary open-angle glaucoma. Journal of Molecular Medicine, 104(1), Article 114. https://doi.org/10.1007/s00109-026-02717-2

Image Credits: AI Generated

DOI: 10.1007/s00109-026-02717-2

Keywords: primary open-angle glaucoma, FXN, frataxin, CTCF, oxidative stress, retinal ganglion cells, reactive oxygen species, biomarker, transcriptional regulation, machine learning, mitochondria, neurodegeneration